On the other hand, inhibition of DPP-IV in T2DM patients results in increased incretin levels of GLP-1, which, in turn, inhibits glucagon release, enhances insulin secretion, and improves glucose tolerance [9]. The gene discussed is GCG; the disease is type 2 diabetes mellitus.